Buscar
Mostrando ítems 1-10 de 10
Pre-Exposure Prophylaxis for viral infections other than HIV
(Infezioni in Medicina, 2022)
The battle against human viral infections has histori-cally relied on two medical strategies, namely vaccines to protect from contagion and antivirals to treat infected patients. In the absence of vaccines, antivirals have ...
Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy
(Drug Design, Development and Therapy, 2023)
It has been ten years since the identification of NTCP as the cell surface receptor for HBV and HDV entry into hepatocytes. The search for molecules interfering with the binding of NTCP and HBV/HDV led to design bulevirtide ...
Is SARS-CoV-2 the only cause of long-COVID?
(AIDS Reviews, 2022)
Around 10% of adults infected with SARS-CoV-2 that survive a first episode of COVID-19 appear to experience long-term clinical manifestations. The signs and symptoms of this post-acute COVID-19 syndrome (PACS) include ...
Increased incidence of giant cell arteritis and associated stroke during the COVID-19 pandemic in Spain: A nation-wide population study
(Autoimmunity Reviews, 2023)
INTRODUCTION: SARS-CoV-2 infection and COVID-19 vaccines might have increased the incidence of giant-cell arteritis (GCA) and the risk of associated stroke in Spain.
METHODS: Retrospective nation-wide observational ...
Impact of the COVID-19 pandemic on hospital admissions due to viral hepatitis in Spain
(Journal of Clinical Virology, 2023)
Background: Before the advent of COVID-19 vaccines, hospitalizations due to SARS-CoV-2 infection during 2020 collapsed most medical centers worldwide. Disruptions in health care for clinical conditions other than COVID-19 ...
Treatment of hepatitis delta and HIV infection
(Liver International, 2023)
Hepatitis delta virus (HDV) is a defective agent that only infects individuals with hepatitis B virus (HBV). Around 5–10% of chronic hepatitis B patients worldwide are superinfected with HDV, which means 15–25 million ...
Safety considerations in the management of hepatitis C and HIV co-infection
(Expert Opinion on Drug Safety, 2023)
Introduction: Both HCV and HIV are highly prevalent infections with current estimates of 57 and 38 million people infected worldwide, respectively. Oral antivirals can be curative for HCV and rescue HIV patients from disease ...
Predictors of in-hospital mortality in HIV-infected patients with COVID-19
(QJM: An International Journal of Medicine, 2023)
Background Underlying immunodeficiency is associated with severe COVID-19, but the prognosis of persons with human immunodeficiency virus (HIV) (PWH) with COVID-19 is under debate. Aim: assessment of the mortality rate and ...
Prospects for Controlling Hepatitis B Globally
(Pathogens, 2024)
Infection with the hepatitis B virus (HBV) is highly prevalent globally. Over 250 million people suffer from chronic hepatitis B, and more than 800,000 patients die each year due to hepatitis B complications, including ...
Pre-exposure prophylaxis of non-HIV viral infections and the role of long-acting antivirals
(AIDS Review, 2023)
Viruses cause a large burden of human infectious diseases. During the past 50 years, antivirals have been developed to treat many pathogenic viruses, including herpesviruses, retroviruses, hepatitis viruses, and influenza. ...





